"BRCAness" syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations

Journal of Clinical Oncology

Volumn 26, Issue 34, 2008, Pages 5530-5536

  Tan, David S P ^a   Rothermundt, Christian ^a   Thomas, Karen ^a   Bancroft, Elizabeth ^a   Eeles, Rosalind ^a   Shanley, Susan ^a   Ardern Jones, Audrey ^a   Norman, Andrew ^a   Kaye, Stanley B ^a   Gore, Martin E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PLATINUM DERIVATIVE;

ADULT; ARTICLE; CANCER RELAPSE; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; RECURRENCE; TREATMENT OUTCOME;

EID: 57149093237     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.1703     Document Type: Article

References (32)

1. Brose MS, Rebbeck TR, Calzone KA, et al: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365-1372, 2002
2. Ford D, Easton DF, Bishop DT, et al: Risks of cancer in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Lancet 343:692-695, 1994
3. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689, 1998
4. Robles-Díaz L, Goldfrank DJ, Kauff ND, et al: Hereditary ovarian cancer in Ashkenazi Jews. Fam Cancer 3:259-264, 2004
5. Calderon-Margalit R, Paltiel O: Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: A critical review of the literature. Int J Cancer 112:357-364, 2004
6. Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615, 2002
7. Aida H, Takakuwa K, Nagata H, et al: Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res 4:235-240, 1998
8. Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al: Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 20:463-466, 2002
9. Rubin SC, Benjamin I, Behbakht K, et al: Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335:1413-1416, 1996
10. Boyd J, Sonoda Y, Federici MG, et al: Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283:2260-2265, 2000
11. Cass I, Baldwin RL, Varkey T, et al: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187-2195, 2003
12. Majdak EJ, Debniak J, Milczek T, et al: Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 104:1004-1012, 2005
13. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, et al: Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The national Israeli study of ovarian cancer. J Clin Oncol 26:20-25, 2008
14. Jóhannsson OT, Ranstam J, Borg A, et al: Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden. J Clin Oncol 16:397-404, 1998
15. Pharoah PD, Easton DF, Stockton DL, et al: Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer United Kingdom Coordinating Committee for Cancer Res (UKCCCR) Familial Ovarian Cancer Study Group Cancer Res 59:868-871, 1999
16. Thigpen T, Brady MF, Omura GA, et al: Age as a prognostic factor in ovarian carcinoma: The Gynecologic Oncology Group experience. Cancer 71:606-614, 1993
17. Winter WE III, Maxwell GL, Tian C, et al: Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 25:3621-3627, 2007
18. Cannistra SA: BRCA1 mutations and survival in women with ovarian cancer. N Engl J Med 336:1254; author reply 1256-1257, 1997
19. Modan B: BRCA1 mutations and survival in women with ovarian cancer. N Engl J Med 336:1255, 1997
20. Tutt A, Ashworth A: The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 8:571-576, 2002
21. Yoshida K, Miki Y: Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 95:866-871, 2004
22. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005
23. Tutt AN, Lord CJ, McCabe N, et al: Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 70:139-148, 2005
24. Yap TA, Boss DS, Fong PC, et al: First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers. J Clin Oncol 25:145s, 2007 (suppl; abstr 3529)
25. Quinn JE, James CR, Stewart GE, et al: BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 13:7413-7420, 2007
26. Pal T, Permuth-Wey J, Kapoor R, et al: Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer 6:113-119, 2007
27. Stratton JF, Gayther SA, Russell P, et al: Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 336:1125-1130, 1997
28. Rustin GJ, Quinn M, Thigpen T, et al: Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 96:487-488, 2004
29. Tassone P, Tagliaferri P, Perricelli A, et al: BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88:1285-1291, 2003
30. Geisler JP, Hatterman-Zogg MA, Rathe JA, et al: Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 94:61-67, 2002
31. Esteller M, Silva JM, Dominguez G, et al: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92:564-569, 2000
32. Hilton JL, Geisler JP, Rathe JA, et al: Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 94:1396-1406, 2002